日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)

贝伐珠单抗联合每周一次阿奈妥单抗或每周一次紫杉醇治疗铂类耐药/难治性高级别卵巢癌的随机 II 期研究(NCI 试验)

Alqaisi, Husam A; Cohn, David E; Chern, Jing-Yi; Duska, Linda R; Jewell, Andrea; Corr, Bradley R; Winer, Ira Seth; Girda, Eugenia; Crispens, Marta A; Dhani, Neesha C; Madariaga, Ainhoa; Grant, Robert C; Malaguti, Matthew; Lee, Crystal; Bowering, Valerie; Wong, Horace; Poothullil, Andrew; Speers, Vanessa; Wang, Lisa; Bedard, Philippe L; Brady, John C; Nixon, Andrew B; Chen, Li; O'Connor, Claire; Zamboni, William; McKee, Tawyna; Moscow, Jeffrey A; Oza, Amit M; Lheureux, Stephanie

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer

评估先天免疫系统、体型和性别对癌症患者阿奈妥单抗拉夫坦辛药代动力学和药效学的影响

Chen, Li; Lucas, Andrew T; Mansfield, Aaron S; Lheureux, Stephanie; O'Connor, Claire; Zamboni, Beth A; Patel, Kashish; McKee, Tawnya; Moscow, Jeffrey; Zamboni, William C

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.

在多细胞类型肿瘤球体中,对靶向药物与 PI3K 抑制剂 inavolisib、alpelisib、duvelisib 和 copanlisib 进行组合筛选

Dexheimer Thomas S, Davoudi Zahra, Coussens Nathan P, Silvers Thomas, Morris Joel, Takebe Naoko, Said Rabih, Moscow Jeffrey A, Doroshow James H, Teicher Beverly A

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis

一个包含基因组和病理注释的泛癌患者来源异种移植组织学图像库可实现深度学习分析

White, Brian S; Woo, Xing Yi; Koc, Soner; Sheridan, Todd; Neuhauser, Steven B; Wang, Shidan; Evrard, Yvonne A; Chen, Li; Foroughi Pour, Ali; Landua, John D; Mashl, R Jay; Davies, Sherri R; Fang, Bingliang; Raso, Maria Gabriela; Evans, Kurt W; Bailey, Matthew H; Chen, Yeqing; Xiao, Min; Rubinstein, Jill C; Sanderson, Brian J; Lloyd, Michael W; Domanskyi, Sergii; Dobrolecki, Lacey E; Fujita, Maihi; Fujimoto, Junya; Xiao, Guanghua; Fields, Ryan C; Mudd, Jacqueline L; Xu, Xiaowei; Hollingshead, Melinda G; Jiwani, Shahanawaz; Acevedo, Saul; Davis-Dusenbery, Brandi N; Robinson, Peter N; Moscow, Jeffrey A; Doroshow, James H; Mitsiades, Nicholas; Kaochar, Salma; Pan, Chong-Xian; Carvajal-Carmona, Luis G; Welm, Alana L; Welm, Bryan E; Govindan, Ramaswamy; Li, Shunqiang; Davies, Michael A; Roth, Jack A; Meric-Bernstam, Funda; Xie, Yang; Herlyn, Meenhard; Ding, Li; Lewis, Michael T; Bult, Carol J; Dean, Dennis A 2nd; Chuang, Jeffrey H

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

奥希替尼治疗表皮生长因子受体突变患者的II期研究:NCI-MATCH ECOG-ACRIN (EAY131)试验子方案E的结果

Chen, Monica F; Song, Zihe; Yu, Helena A; Sequist, Lecia V; Lovly, Christine M; Mitchell, Edith P; Moscow, Jeffrey A; Gray, Robert J; Wang, Victoria; McShane, Lisa M; Rubinstein, Larry V; Patton, David R; Williams, P Mickey; Hamilton, Stanley R; Umemura, Yoshie; Tricoli, James V; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

患者来源异种移植瘤生长和抗肿瘤活性的评估:NCI PDXNet 共识建议

Meric-Bernstam, Funda; Lloyd, Michael W; Koc, Soner; Evrard, Yvonne A; McShane, Lisa M; Lewis, Michael T; Evans, Kurt W; Li, Dali; Rubinstein, Lawrence; Welm, Alana; Dean, Dennis A 2nd; Srivastava, Anuj; Grover, Jeffrey W; Ha, Min J; Chen, Huiqin; Huang, Xuelin; Varadarajan, Kaushik; Wang, Jing; Roth, Jack A; Welm, Bryan; Govinden, Ramaswamy; Ding, Li; Kaochar, Salma; Mitsiades, Nicholas; Carvajal-Carmona, Luis; Herylyn, Meenhard; Davies, Michael A; Shapiro, Geoffrey I; Fields, Ryan; Trevino, Jose G; Harrell, Joshua C; Doroshow, James H; Chuang, Jeffrey H; Moscow, Jeffrey A

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

一项随机试验比较了阿奈妥单抗拉夫坦辛联合帕博利珠单抗与帕博利珠单抗单药治疗间皮瘤的疗效

Mansfield, Aaron S; Vivien Yin, Jun; Bradbury, Penelope; Kwiatkowski, David J; Patel, Shiven; Bazhenova, Lyudmila A; Forde, Patrick; Lou, Yanyan; Dizona, Paul; Villaruz, Liza C; Arnold, Susanne M; Khalil, Maya; Kindler, Hedy L; Koczywas, Marianna; Pacheco, Jose; Rolfo, Christian; Xia, Bing; Mikula, Elizabeth; Chen, Li; Patel, Kashish; Smith, Katherine E R; Cao, Liang; Shapiro, Geoffrey; Costello, Brian A; Adjei, Alex; Sharon, Elad; Moscow, Jeffrey A; Zamboni, William; Hassan, Raffit

Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.

在多细胞类型肿瘤球体中进行的组合筛选揭示了芳烃受体拮抗剂与 E1 泛素激活酶抑制剂之间的相互作用

Dexheimer Thomas S, Coussens Nathan P, Silvers Thomas, Jones Eric M, Chen Li, Fang Jianwen, Morris Joel, Moscow Jeffrey A, Doroshow James H, Teicher Beverly A

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

美国国家癌症研究所联合治疗平台试验:基于分子分析的治疗选择(ComboMATCH)

Meric-Bernstam, Funda; Ford, James M; O'Dwyer, Peter J; Shapiro, Geoffrey I; McShane, Lisa M; Freidlin, Boris; O'Cearbhaill, Roisin E; George, Suzanne; Glade-Bender, Julia; Lyman, Gary H; Tricoli, James V; Patton, David; Hamilton, Stanley R; Gray, Robert J; Hawkins, Douglas S; Ramineni, Bhanumati; Flaherty, Keith T; Grivas, Petros; Yap, Timothy A; Berlin, Jordan; Doroshow, James H; Harris, Lyndsay N; Moscow, Jeffrey A

The New NCI Precision Medicine Trials

美国国家癌症研究所精准医疗新试验

Harris, Lyndsay N; Blanke, Charles D; Erba, Harry P; Ford, James M; Gray, Robert J; LeBlanc, Michael L; Hu-Lieskovan, Siwen; Litzow, Mark R; Luger, Selina M; Meric-Bernstam, Funda; O'Dwyer, Peter J; Othus, Megan K D; Politi, Katerina; Shepherd, Lois E; Allegra, Carmen J; Chen, Helen X; Ivy, S Percy; Korde, Larissa A; Little, Richard F; McShane, Lisa M; Moscow, Jeffrey A; Patton, David R; Thurin, Magdalena; Yee, Laura M; Doroshow, James H